Journal of Clinical Oncology, Vol 12, 2013-2021, Copyright © 1994 by American Society of Clinical Oncology

ARTICLES

Chemotherapy for anaplastic oligodendroglioma. National Cancer Institute of Canada Clinical Trials Group

G Cairncross, D Macdonald, S Ludwin, D Lee, T Cascino, J Buckner, D Fulton, E Dropcho, D Stewart and C Schold Jr
Department of Clinical Neurological Sciences, University of Western Ontario, London, Canada.

PURPOSE: To examine the rate and duration of response of anaplastic oligodendrogliomas to a dose-escalated combination chemotherapy regimen consisting of procarbazine, lomustine (CCNU), and vincristine (PCV) and to evaluate the side effects of this treatment. METHODS: In this single- arm multicentered phase II study, patients with measurable, newly diagnosed or recurrent, contrast-enhancing anaplastic oligodendrogliomas were treated with up to six cycles of PCV. Central pathology and radiology review were mandatory, and rigorous response criteria based on imaging were used. RESULTS: Thirty-three patients entered the trial; nine were excluded subsequently, seven due to ineligible pathology. Eighteen of 24 eligible patients (75%) responded, nine completely (38%), four had stable disease (SD), and two progressed during the first cycle of PCV. Responses were observed in nine of 10 patients (90%) with a preexisting low-grade oligodendroglioma and 10 of 15 (67%) with necrotic tumors, called glioblastoma multiforme by some. Previously irradiated patients were as likely to respond to PCV as those newly diagnosed (11 of 15 [73%] v seven of nine [78%]). The median time to progression will be at least 25.2 months for complete responders, and was 14.2 months for partial responders and 6.8 months for stable patients. Four ineligible patients also responded to PCV; all had gliomas with oligodendroglial differentiation. All responders, eligible or ineligible, were stable or improved neurologically, but nine of 22 (41%) experienced a decline in Eastern Cooperative Oncology Group (ECOG) performance status of one grade while on PCV. Adverse events on treatment included a death from Pneumocystis pneumonia, a severe reversible encephalopathy due to procarbazine, an intratumoral hemorrhage, and a subdural hematoma. All other acute toxicities were anticipated and manageable. CONCLUSION: Anaplastic oligodendrogliomas are chemosensitive brain cancers. Patients with these tumors respond predictably, durably, and often completely to PCV, and many tolerate a dose-escalated formulation. Cooperative group and randomized trials will be necessary to explore fully the role of chemotherapy in the treatment of aggressive oligodendrogliomas.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Taillibert, L. A. Vincent, B. Granger, Y. Marie, C. Carpentier, R. Guillevin, A. Bellanger, K. Mokhtari, A. Rousseau, D. Psimaras, et al. Bevacizumab and irinotecan for recurrent oligodendroglial tumors Neurology, May 5, 2009; 72(18): 1601 - 1606. [Abstract] [Full Text] [PDF]

				J. E. C. Bromberg and M. J. van den Bent Oligodendrogliomas: Molecular Biology and Treatment Oncologist, February 1, 2009; 14(2): 155 - 163. [Abstract] [Full Text] [PDF]

				M. A. Vogelbaum, B. Berkey, D. Peereboom, D. Macdonald, C. Giannini, J. H. Suh, R. Jenkins, J. Herman, P. Brown, D. T. Blumenthal, et al. Phase II trial of preirradiation and concurrent temozolomide in patients with newly diagnosed anaplastic oligodendrogliomas and mixed anaplastic oligoastrocytomas: RTOG BR0131 Neuro-oncol, January 1, 2009; 11(2): 167 - 175. [Abstract] [Full Text] [PDF]

				A. B. Lassman Management of Newly Diagnosed Anaplastic Oligodendrogliomas ASCO Educational Book, January 1, 2009; 2009(1): 85 - 89. [Abstract] [Full Text] [PDF]

				W. P. Mason and J. G. Cairncross Invited Article: The expanding impact of molecular biology on the diagnosis and treatment of gliomas Neurology, July 29, 2008; 71(5): 365 - 373. [Abstract] [Full Text] [PDF]

				M. J.B. Taphoorn, M. J. van den Bent, M. E.L. Mauer, C. Coens, J.-Y. Delattre, A. A. Brandes, P. A.E. Sillevis Smitt, H. J.J.A. Bernsen, M. Frenay, C. C. Tijssen, et al. Health-Related Quality of Life in Patients Treated for Anaplastic Oligodendroglioma With Adjuvant Chemotherapy: Results of a European Organisation for Research and Treatment of Cancer Randomized Clinical Trial J. Clin. Oncol., December 20, 2007; 25(36): 5723 - 5730. [Abstract] [Full Text] [PDF]

				J. C. Buckner, P. D. Brown, B. P. O'Neill, F. B. Meyer, C. J. Wetmore, and J. H. Uhm Central Nervous System Tumors Mayo Clin. Proc., October 1, 2007; 82(10): 1271 - 1286. [Abstract] [Full Text] [PDF]

				A. A. Brandes, A. Tosoni, G. Cavallo, M. Reni, E. Franceschi, L. Bonaldi, R. Bertorelle, M. Gardiman, C. Ghimenton, P. Iuzzolino, et al. Correlations Between O6-Methylguanine DNA Methyltransferase Promoter Methylation Status, 1p and 19q Deletions, and Response to Temozolomide in Anaplastic and Recurrent Oligodendroglioma: A Prospective GICNO Study J. Clin. Oncol., October 10, 2006; 24(29): 4746 - 4753. [Abstract] [Full Text] [PDF]

				S. A. Grossman, K. A. Carson, T. T. Batchelor, G. Lesser, T. Mikkelsen, J. B. Alavi, S. Phuphanich, T. Hammour, J. D. Fisher, and J. G. Supko The Effect of Enzyme-Inducing Antiseizure Drugs on the Pharmacokinetics and Tolerability of Procarbazine Hydrochloride Clin. Cancer Res., September 1, 2006; 12(17): 5174 - 5181. [Abstract] [Full Text] [PDF]

				G. Cairncross, B. Berkey, E. Shaw, R. Jenkins, B. Scheithauer, D. Brachman, J. Buckner, K. Fink, L. Souhami, N. Laperierre, et al. Phase III Trial of Chemotherapy Plus Radiotherapy Compared With Radiotherapy Alone for Pure and Mixed Anaplastic Oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402 J. Clin. Oncol., June 20, 2006; 24(18): 2707 - 2714. [Abstract] [Full Text] [PDF]

				M. J. van den Bent, A. F. Carpentier, A. A. Brandes, M. Sanson, M. J.B. Taphoorn, H. J.J.A. Bernsen, M. Frenay, C. C. Tijssen, W. Grisold, L. Sipos, et al. Adjuvant Procarbazine, Lomustine, and Vincristine Improves Progression-Free Survival but Not Overall Survival in Newly Diagnosed Anaplastic Oligodendrogliomas and Oligoastrocytomas: A Randomized European Organisation for Research and Treatment of Cancer Phase III Trial J. Clin. Oncol., June 20, 2006; 24(18): 2715 - 2722. [Abstract] [Full Text] [PDF]

				L. E. Abrey, B. H. Childs, N. Paleologos, L. Kaminer, S. Rosenfeld, D. Salzman, J. L. Finlay, S. Gardner, K. Peterson, W. Hu, et al. High-dose chemotherapy with stem cell rescue as initial therapy for anaplastic oligodendroglioma: Long-term follow-up Neuro-oncol, April 1, 2006; 8(2): 183 - 188. [Abstract] [Full Text] [PDF]

				F. F. Lang and M. R. Gilbert Diffusely Infiltrative Low-Grade Gliomas in Adults J. Clin. Oncol., March 10, 2006; 24(8): 1236 - 1245. [Abstract] [Full Text] [PDF]

				R. Stupp, M. E. Hegi, M. J. van den Bent, W. P. Mason, M. Weller, R. O. Mirimanoff, J. G. Cairncross, and on behalf of the European Organisation for Researc Changing paradigms--an update on the multidisciplinary management of malignant glioma. Oncologist, February 1, 2006; 11(2): 165 - 180. [Abstract] [Full Text] [PDF]

				A. U. Ty, S. J. See, J. P. Rao, J.B.K. Khoo, and M. C. Wong Oligodendroglial tumor chemotherapy using "decreased-dose-intensity" PCV: A Singapore experience Neurology, January 24, 2006; 66(2): 247 - 249. [Abstract] [Full Text] [PDF]

				K. K. Koeller and E. J. Rushing From the Archives of the AFIP: Oligodendroglioma and Its Variants: Radiologic-Pathologic Correlation RadioGraphics, November 1, 2005; 25(6): 1669 - 1688. [Abstract] [Full Text] [PDF]

				E. N. Eskandar, J. S. Loeffler, A. M. O'Neill, G. J. Hunter, and D. N. Louis Case 33-2004 - A 34-Year-Old Man with a Seizure and a Frontal-Lobe Brain Lesion N. Engl. J. Med., October 28, 2004; 351(18): 1875 - 1882. [Full Text] [PDF]

				V. H.J.M. Triebels, M. J.B. Taphoorn, A. A. Brandes, J. Menten, M. Frenay, A. Tosoni, J. M. Kros, E. B.-t. Stege, R. H. Enting, A. Allgeier, et al. Salvage PCV chemotherapy for temozolomide-resistant oligodendrogliomas Neurology, September 14, 2004; 63(5): 904 - 906. [Abstract] [Full Text] [PDF]

				K. Hoang-Xuan, L. Capelle, M. Kujas, S. Taillibert, H. Duffau, J. Lejeune, M. Polivka, E. Criniere, Y. Marie, K. Mokhtari, et al. Temozolomide As Initial Treatment for Adults With Low-Grade Oligodendrogliomas or Oligoastrocytomas and Correlation With Chromosome 1p Deletions J. Clin. Oncol., August 1, 2004; 22(15): 3133 - 3138. [Abstract] [Full Text] [PDF]

				M. Sanson, S. Cartalat-Carel, S. Taillibert, M. Napolitano, L. Djafari, J. Cougnard, H. Gervais, F. Laigle, A. Carpentier, K. Mokhtari, et al. Initial chemotherapy in gliomatosis cerebri Neurology, July 27, 2004; 63(2): 270 - 275. [Abstract] [Full Text] [PDF]

				M. Brada, L. Viviers, C. Abson, F. Hines, J. Britton, S. Ashley, S. Sardell, D. Traish, A. Gonsalves, P. Wilkins, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas Ann. Onc., December 1, 2003; 14(12): 1715 - 1721. [Abstract] [Full Text] [PDF]

				M.J. van den Bent, M.J.B. Taphoorn, A.A. Brandes, J. Menten, R. Stupp, M. Frenay, O. Chinot, J.M. Kros, C.C.D. van der Rijt, Ch.J. Vecht, et al. Phase II Study of First-Line Chemotherapy With Temozolomide in Recurrent Oligodendroglial Tumors: The European Organization for Research and Treatment of Cancer Brain Tumor Group Study 26971 J. Clin. Oncol., July 1, 2003; 21(13): 2525 - 2528. [Abstract] [Full Text] [PDF]

				H. A. Fine, P. Y. Wen, E. A. Maher, E. Viscosi, T. Batchelor, N. Lakhani, W. D. Figg, B. W. Purow, and C. B. Borkowf Phase II Trial of Thalidomide and Carmustine for Patients With Recurrent High-Grade Gliomas J. Clin. Oncol., June 15, 2003; 21(12): 2299 - 2304. [Abstract] [Full Text] [PDF]

				M. van den Bent, O.-L. Chinot, and J. G. Cairncross Recent developments in the molecular characterization and treatment of oligodendroglial tumors Neuro-oncol, April 1, 2003; 5(2): 128 - 138. [Abstract] [PDF]

				M. J. van den Bent, O. Chinot, W. Boogerd, J. Bravo Marques, M. J. B. Taphoorn, J. M. Kros, C. C. D. van der Rijt, C. J. Vecht, N. De Beule, and B. Baron Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972 Ann. Onc., April 1, 2003; 14(4): 599 - 602. [Abstract] [Full Text] [PDF]

				J. C. Buckner, D. Gesme Jr, J. R. O'Fallon, J. E. Hammack, S. Stafford, P. D. Brown, R. Hawkins, B. W. Scheithauer, B. J. Erickson, R. Levitt, et al. Phase II Trial of Procarbazine, Lomustine, and Vincristine as Initial Therapy for Patients With Low-Grade Oligodendroglioma or Oligoastrocytoma: Efficacy and Associations With Chromosomal Abnormalities J. Clin. Oncol., January 15, 2003; 21(2): 251 - 255. [Abstract] [Full Text] [PDF]

				E. Shaw, R. Arusell, B. Scheithauer, J. O'Fallon, B. O'Neill, R. Dinapoli, D. Nelson, J. Earle, C. Jones, T. Cascino, et al. Prospective Randomized Trial of Low- Versus High-Dose Radiation Therapy in Adults With Supratentorial Low-Grade Glioma: Initial Report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study J. Clin. Oncol., May 1, 2002; 20(9): 2267 - 2276. [Abstract] [Full Text] [PDF]

				D. N. Louis, E. C. Holland, and J. G. Cairncross Glioma Classification : A Molecular Reappraisal Am. J. Pathol., September 1, 2001; 159(3): 779 - 786. [Full Text] [PDF]

				M.J. van den Bent, F. Keime-Guibert, A.A. Brandes, M.J.B. Taphoorn, J.M. Kros, F.A.L.M. Eskens, and A.F. Carpentier Temozolomide chemotherapy in recurrent oligodendroglioma Neurology, July 24, 2001; 57(2): 340 - 342. [Abstract] [Full Text] [PDF]

				U Schlegel, H Pels, A Glasmacher, R Kleinschmidt, I Schmidt-Wolf, C Helmstaedter, K Fliessbach, M Deckert, D Van Roost, R Fimmers, et al. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study J. Neurol. Neurosurg. Psychiatry, July 1, 2001; 71(1): 118 - 122. [Abstract] [Full Text] [PDF]

				H. Sasaki, M. C. Zlatescu, R. A. Betensky, Y. Ino, J. G. Cairncross, and D. N. Louis PTEN Is a Target of Chromosome 10q Loss in Anaplastic Oligodendrogliomas and PTEN Alterations Are Associated with Poor Prognosis Am. J. Pathol., July 1, 2001; 159(1): 359 - 367. [Abstract] [Full Text] [PDF]

				O.-L. Chinot, S. Honore, H. Dufour, M. Barrie, D. Figarella-Branger, X. Muracciole, D. Braguer, P.-M. Martin, and F. Grisoli Safety and Efficacy of Temozolomide in Patients With Recurrent Anaplastic Oligodendrogliomas After Standard Radiotherapy and Chemotherapy J. Clin. Oncol., May 1, 2001; 19(9): 2449 - 2455. [Abstract] [Full Text] [PDF]

				L. M. DeAngelis Brain Tumors N. Engl. J. Med., January 11, 2001; 344(2): 114 - 123. [Full Text] [PDF]

				A.C. Kappelle, T.J. Postma, M.J.B. Taphoorn, G.J. Groeneveld, M.J. van den Bent, C.J. van Groeningen, B.A. Zonnenberg, K.C.A. Sneeuw, and J.J. Heimans PCV chemotherapy for recurrent glioblastoma multiforme Neurology, January 9, 2001; 56(1): 118 - 120. [Abstract] [Full Text] [PDF]

				C. L. Nutt, M. Noble, A. F. Chambers, and J. G. Cairncross Differential Expression of Drug Resistance Genes and Chemosensitivity in Glial Cell Lineages Correlate with Differential Response of Oligodendrogliomas and Astrocytomas to Chemotherapy Cancer Res., September 1, 2000; 60(17): 4812 - 4818. [Abstract] [Full Text]

				R. E. McLendon, C. J. Wikstrand, M. R. Matthews, R. Al-Baradei, S. H. Bigner, and D. D. Bigner Glioma-associated Antigen Expression in Oligodendroglial Neoplasms: Tenascin and Epidermal Growth Factor Receptor J. Histochem. Cytochem., August 1, 2000; 48(8): 1103 - 1110. [Abstract] [Full Text]

				J. D. Olson, E. Riedel, and L. M. DeAngelis Long-term outcome of low-grade oligodendroglioma and mixed glioma Neurology, April 11, 2000; 54(7): 1442 - 1448. [Abstract] [Full Text] [PDF]

				G. Cairncross, L. Swinnen, R. Bayer, S. Rosenfeld, D. Salzman, N. Paleologos, L. Kaminer, P. Forsyth, D. Stewart, K. Peterson, et al. Myeloablative chemotherapy for recurrent aggressive oligodendroglioma Neuro-oncol, April 1, 2000; 2(2): 114 - 119. [Abstract] [PDF]

				J. S. Smith, A. Perry, T. J. Borell, H. K. Lee, J. O’Fallon, S. M. Hosek, D. Kimmel, A. Yates, P. C. Burger, B. W. Scheithauer, et al. Alterations of Chromosome Arms 1p and 19q as Predictors of Survival in Oligodendrogliomas, Astrocytomas, and Mixed Oligoastrocytomas J. Clin. Oncol., February 1, 2000; 18(3): 636 - 636. [Abstract] [Full Text] [PDF]

				N. A. Paleologos, D. R. Macdonald, N. A. Vick, and J. G. Cairncross Neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma Neurology, September 1, 1999; 53(5): 1141 - 1141. [Abstract] [Full Text]

				W. R. Shapiro Current Therapy for Brain Tumors: Back to the Future Arch Neurol, April 1, 1999; 56(4): 429 - 432. [Abstract] [Full Text] [PDF]

				J. R. Perry, D. N. Louis, and J. G. Cairncross Current Treatment of Oligodendrogliomas Arch Neurol, April 1, 1999; 56(4): 434 - 436. [Full Text] [PDF]

				N. A. Paleologos and J. G. Cairncross Treatment of oligodendroglioma: An update Neuro-oncol, January 1, 1999; 1(1): 61 - 68. [Abstract] [PDF]

				V. A. Levin Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: The past decade and where we are heading Neuro-oncol, January 1, 1999; 1(1): 69 - 80. [Abstract] [PDF]